Try a new search

Format these results:

Searched for:

person:maletp01

in-biosketch:true

Total Results:

14


Nivolumab and Ipilimumab Immunotherapy-Induced Colitis and Hepatitis [Meeting Abstract]

Ballecer, Eric; Sy, Alexander; Miller, Jennifer; Mago, Sheena; Sofer, Tova; Malet, Peter
ISI:000464611004286
ISSN: 0002-9270
CID: 3897722

Angioedema of the small intestine: A great imitator [Case Report]

Alagheband, S; Malet, P; Katz, D; Davis-Lorton, M
PMID: 27825635
ISSN: 2210-741x
CID: 5029502

Upper Gastrointestinal Bleeding Due to Amyloidosis in a Patient With Multiple Myeloma [Case Report]

Singh, Karanprit; Chapalamadugu, Prateek; Malet, Peter
PMID: 27451090
ISSN: 1542-7714
CID: 3467142

Isolated Angiotensin Converting Enzyme (ACE) Inhibitor Induced Small Bowel Angioedema Aft er 10 Years of Oral Lisinopril Therapy [Meeting Abstract]

Razzano, Anthony; Alagheband, Sharzad; Ahmed, Haseeb; Malet, Peter; Katz, Douglas
ISI:000395764603508
ISSN: 0002-9270
CID: 5229372

Red Color Colonoscopy Prep Does Not Affect Endoscopic Visualization: A Pilot Study [Meeting Abstract]

Mogul, Zainab; Saha, Ritu; Rush, Jordan; Vrabie, Raluca; Malet, Peter; Halwan, Bhawna
ISI:000330178100587
ISSN: 0002-9270
CID: 3508372

Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up

Singal, Amit G; Dharia, Tushar D; Malet, Peter F; Alqahtani, Saleh; Zhang, Song; Cuthbert, Jennifer A
OBJECTIVES/OBJECTIVE:To demonstrate the survival benefit from sustained virological response (SVR) in a safety net hospital population with limited resources for hepatitis C virus (HCV) therapy. DESIGN AND SETTING/METHODS:We conducted a retrospective study at an urban safety net hospital in the USA. PARTICIPANTS AND INTERVENTION/METHODS:242 patients receiving standard HCV therapy between 2001 and 2006. PRIMARY AND SECONDARY OUTCOME MEASURES/METHODS:Response rates, including SVR, were recorded for each patient. Univariate and multivariate analyses were performed to identify predictors of SVR and 5-year survival. RESULTS:A total of 242 eligible patients were treated. Treatment was completed in 197 (81%) patients, with 43 patients discontinuing therapy early-32 due to adverse events and 11 due to non-compliance. Complications on treatment were frequent, including three deaths. SVR was achieved in 83 patients (34%). On multivariate analysis, independent predictors of a decreased likelihood of achieving SVR included African-American race (OR 0.20, 95% CI 0.07 to 0.54), genotype 1 HCV infection (OR 0.25, 95% CI 0.13 to 0.50) and the presence of cirrhosis (OR 0.26, 95% CI 0.12 to 0.58). Survival was 98% in those achieving SVR (median follow-up 72 months) and 71% in non-responders and those discontinuing therapy (n=91, median known follow-up 65 and 36 months, respectively). On multivariate analysis, the only independent predictor of improved survival was SVR (HR 0.12, 95% CI 0.03 to 0.52). Both cirrhosis and hypoalbuminaemia were independent predictors of increased mortality. CONCLUSIONS:Treatment before histological cirrhosis develops, in combination with careful selection, may improve long-term outcomes without compromising other healthcare endeavours in safety net hospitals and areas with financial limitations.
PMID: 24002983
ISSN: 2044-6055
CID: 3467132

High yield of same-session EUS-guided liver biopsy by 19-gauge FNA needle in patients undergoing EUS to exclude biliary obstruction

Stavropoulos, Stavros N; Im, Gene Y; Jlayer, Zahra; Harris, Michael D; Pitea, Teodor C; Turi, George K; Malet, Peter F; Friedel, David M; Grendell, James H
BACKGROUND:EUS-guided liver biopsy by Trucut yields variable specimen adequacy at high cost, limiting its utility. A modified EUS-guided technique with reliable adequacy could be a viable alternative to standard techniques in cost-effective clinical settings. OBJECTIVE:To describe our experience with EUS-guided liver biopsy by 19-gauge FNA, non-Trucut, needle in a cost-effective setting: patients with abnormal liver test results of unclear etiology referred for EUS to exclude biliary obstruction in whom an unrevealing EUS would have prompted a next-step liver biopsy by the referring physician. DESIGN/METHODS:Prospective case series. SETTING/METHODS:Tertiary-care teaching hospital. PATIENTS/METHODS:Consecutive patients with abnormal liver tests referred for EUS. INTERVENTIONS/METHODS:EUS-guided liver biopsy by 19-gauge FNA needle (non-Trucut). MAIN OUTCOME MEASUREMENTS/METHODS:Diagnostic yield, specimen adequacy, and complications. An adequate specimen was defined as a length of 15 mm or longer and 6 or more complete portal tracts (CPTs). RESULTS:Between July 2008 and July 2011, 22 of 31 consecutive patients meeting inclusion criteria underwent unrevealing EUS with same-session EUS-guided liver biopsy by 19-gauge FNA needle. A median of 2 FNA passes (range 1-3) yielded a median specimen length of 36.9 mm (range 2-184.6 mm) with a median of 9 CPTs (range 1-73 CPTs). EUS-guided liver biopsies yielded a histologic diagnosis and adequate specimens in 20 of 22 patients (91%). Expanded experience led to improved specimen adequacy. There were no complications. LIMITATION/CONCLUSIONS:Small study size. CONCLUSIONS:EUS-guided liver biopsy by using a 19-gauge FNA needle appears to be feasible and safe and provides excellent diagnostic yield and specimen adequacy.
PMID: 22248599
ISSN: 1097-6779
CID: 3276342

HIGH YIELD OF SAME SESSION ENDOSCOPIC ULTRASOUND (EUS)-GUIDED LIVER BIOPSY BY 19-GAUGE FINE NEEDLE ASPIRATION (FNA) OF BENIGN HEPATIC PARENCHYMAL DISEASE IN PATIENTS UNDERGOING EUS FOR SUSPECTED BILIARY OBSTRUCTION [Meeting Abstract]

Im, Gene Y.; Jlayer, Zahra; Harris, Michael; Pitea, Teodor C.; Malet, Peter F.; Grendell, James H.; Friedel, David M.; Turi, George K.; Stavropoulos, Stavros N.
ISI:000295578003358
ISSN: 0270-9139
CID: 3521512

Feasibility of Same Session EUS-Guided Liver Biopsy After Negative EUS in Patients Referred for Abnormal Liver Enzymes and Suspected Biliary Obstruction [Meeting Abstract]

Im, Gene Y.; Grendell, James H.; Turi, George K.; Malet, Peter F.; Jlayer, Zahra; Stavropoulos, Stavros N.
ISI:000276710400138
ISSN: 0016-5107
CID: 3276422

Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis

Bonkovsky, Herbert L; Snow, Kristin K; Malet, Peter F; Back-Madruga, Carla; Fontana, Robert J; Sterling, Richard K; Kulig, Clark C; Di Bisceglie, Adrian M; Morgan, Timothy R; Dienstag, Jules L; Ghany, Marc G; Gretch, David R
BACKGROUND/AIMS/OBJECTIVE:Although the antiviral and histological benefits of peginterferon/ribavirin therapy are well established, the effects on health-related quality of life (HRQOL) and sexual health are less certain. This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial. METHODS:Subjects completed SF-36 and sexual health questionnaires prior to and after 24 weeks of peginterferon/ribavirin therapy (n=1144). Three hundred and seventy-three (33%) subjects were HCV RNA negative at week 20 and continued therapy through week 48; 258 were seen at week 72. One hundred and eighty achieved sustained virological responses (SVR) and 78 relapsed. RESULTS:At baseline, patients had poorer scores for all eight SF-36 domains compared to healthy controls. Patients with cirrhosis had lower HRQOL scores than those with bridging fibrosis, as did patients with higher depression scores. SVR patients had significant improvements in seven domains, whereas relapsers had significant worsening in one domain. Sexual scores improved in SVR patients and decreased in relapsers (p=0.03). In multivariate analyses, improvements in HRQOL and sexual scores were significantly associated with SVR but were less striking in patients with lower depression scores. CONCLUSIONS:Achievement of SVR after peginterferon/ribavirin therapy improves HRQOL and sexual health in chronic hepatitis C patients with advanced fibrosis or cirrhosis.
PMID: 17196293
ISSN: 0168-8278
CID: 3467122